Safety and antitumour activity of ODM-201 (BAY-1841788) in castration-resistant, CYP17 inhibitor-naïve prostate cancer : results from extended follow-up of the ARADES Trial by Fizazi, Karim et al.
Prostate Cancer
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in
Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer:
Results from Extended Follow-up of the ARADES Trial
Karim Fizazi a,*, Christophe Massard a, Petri Bono b, Vesa Kataja c,y, Nicholas James d,
Teuvo L. Tammela e, Heikki Joensuu b, John Aspegren f, Mika Mustonen f
a Institut Gustave Roussy, University of Paris Sud, Villejuif, France; bComprehensive Cancer Center, Helsinki University Hospital, University of Helsinki,
Helsinki, Finland; cKuopio University Hospital, Kuopio, Finland; dQueen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust,
Birmingham, UK; e Tampere University Hospital, Tampere, Finland; fOrion Corporation, Orion Pharma, Espoo, Finland
E U R O P E A N U R O L O G Y F O C U S 3 ( 2 0 17 ) 6 0 6 – 6 1 4
avai la ble at www.sciencedirect .com
journal homepage: www.europeanurology.com/euf ocus
Article info
Article history:










Background: Patients with castration-resistant prostate cancer (CRPC) had extended
responses to the androgen receptor antagonist ODM-201, in phase 1/2 studies.
Objective: To evaluate the safety and antitumour activity of prolonged ODM-201 treatment
in patients with CRPC.
Design, setting, and participants: The ARADES trial was a multicentre phase 1 (dose
escalation) and phase 2 (dose expansion) trial; 134 patients with CRPC were stratiﬁed
by previous chemotherapy to receive ODM-201. This paper reports extended follow-up in
CYP17 inhibitor (CYP17i)-naïve patients.
Intervention: Patients (n = 77) received oral ODM-201 twice daily at daily doses of 200–
1800 mg.
Outcome measurements and statistical analysis: Safety, measured as the occurrence of
adverse events (AEs), prostate-speciﬁc antigen (PSA), and radiographic progression.
Results and limitations: The safety proﬁle of extended ODM-201 treatment (median
treatment duration 8.2 mo, 95% conﬁdence interval [CI] 5.6–11.0) was consistent with that
reported at the time of the original data cutoff in the main ARADES trial, with no unexpected
safety concerns over time. The majority of AEs (61.1%) were mild (grade 1); the most
common AE was fatigue/asthenia (35.1% of patients), with no clear relationship to ODM-201.
Median time to PSA progression was 25.2 mo (95% CI 11.3–25.2) for chemotherapy-naïve
men and not reached (NR; 95% CI 5.5–NR) for chemotherapy-pretreated patients; a trend for
improved antitumour response was observed for chemotherapy-naïve patients. The median
time to radiographic progression was longer for chemotherapy-naïve (14.0 mo, 95% CI 8.1–
33.3) than for chemotherapy-pretreated (7.2 mo, 95% CI 2.7–11.0) patients.
Conclusions: Prolonged exposure to ODM-201 was well tolerated, with no additional safety
concerns; disease suppression was sustained, especially in chemotherapy-naïve patients.
These data support further development of ODM-201 in men with CYP17i-naïve CRPC.
Patient summary: Extended ODM-201 therapy was well tolerated, with beneﬁcial anti-
tumour activity in men with advanced prostate cancer, indicating that ODM-201 may
represent a new active treatment for men with CRPC.
This extension trial is registered at ClinicalTrials.gov (www.clinicaltrials.gov) under
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Since 1941, when Huggins and Hodges showed that andro-
gen deprivation could inhibit tumour growth in patients
with advanced prostate cancer (PCa) [1], targeting of andro-
gen synthesis and the androgen receptor (AR) pathway
have formed key therapeutic strategies for the treatment
of this cancer [2]. However, as the disease progresses,
resistance to long-term androgen ablation develops and
the majority of patients progress to castration-resistant
prostate cancer (CRPC), which requires subsequent treat-
ment [3,4]. CRPC is associated with poor prognosis and
often with increasing levels of serum prostate-specific
antigen (PSA), indicating that AR signalling continues to
drive the disease [5–7].
The progression of PCa from hormone-sensitive disease
has been extensively investigated, and key known mecha-
nisms include AR gene amplification and mutation, AR over-
expression, and AR stimulation by non-androgen ligands
[8,9]. Therefore, novel second-generation AR antagonists,
such as the nonsteroidal AR antagonists ODM-201, apaluta-
mide, and enzalutamide, have been specifically developed
for CRPC treatment [6,10,11]. ODM-201 is an investigational
oral AR antagonist with a unique chemical structure that is
designed to block the growth of cancer cells by binding to
the AR with high affinity; this inhibits nuclear translocation
and limits the functionality of the receptor. Preclinical stud-
ies showed that ODM-201 inhibits the AR more potently
than other second-generation antiandrogens such as enza-
lutamide and apalutamide; it also displayed more potent
antitumour activity than enzalutamide in a preclinical
model of CRPC characterised by AR amplification and over-
expression [12,13].
Evidence from clinical studies suggested that ODM-201
monotherapy provides disease suppression in men with
progressive CRPC and is well tolerated [13,14]. The first-
in-man phase 1/2 ARADES trial showed that ODM-201 had a
positive safety profile in CYP17 inhibitor (CYP17i)-naïve
patients (chemotherapy-naïve or post-chemotherapy) and
in post-CYP17i patients up to the highest prespecified daily
dose of 1800 mg; the maximum tolerated dose was not
reached [14]. Most adverse events (AEs) were grade 1–2
and were similar within dose levels (200–1800 mg/d); only
5/124 patients (4%) discontinued treatment because of an
AE [14]. In the phase 2 ARADES trial, durable responses were
achieved with all doses tested (200, 400, and 1400 mg/d)
and were more pronounced in CYP17i-naïve men (both
chemotherapy-naïve and chemotherapy-pretreated), than
in post-CYP17i patients. Only three patients (2%) discon-
tinued treatment because of AEs, and these were not related
to ODM-201 exposure.
As treatment for PCa typically entails prolonged hor-
monal therapy, sustained treatment should be well toler-
ated and not result in rapid emergence of acquired resis-
tance to AR antagonists [11]. We analysed the safety and
antitumour activity of ODM-201 in CYP17i-naïve patients
with advanced CRPC (chemotherapy-naïve or chemother-
apy-pretreated) from the extension component of the ARA-
DES trial.2. Patients and methods
2.1. Study design and patients
The current trial is an analysis based on extended follow-up of patients
enrolled in ARADES, an open-label, multicentre trial with two compo-
nents: phase 1 (non-randomised dose escalation) and phase 2 (random-
ised dose expansion). The complete design and methods for ARADES
were published previously [14]. In brief, male patients aged 18 yr with
histologically conﬁrmed adenocarcinoma of the prostate and progressive
metastatic disease were eligible, provided that their serum testosterone
concentration was <0.50 ng/ml; they had received prior ﬁrst-generation
AR antagonist treatment (and withdrawal) and up to two previous
chemotherapy regimens; had Eastern Cooperative Oncology Group per-
formance status of 0/1; and had not received previous therapy with
enzalutamide or an investigational AR antagonist.
2.2. Ethics
This extension trial was approved by the investigational review board or
independent ethics committee of each participating centre. It was con-
ducted according to the principles of the Declaration of Helsinki and in
compliance with Good Clinical Practice guidelines. All patients provided
written informed consent.
2.3. Treatment
In the phase 1/2 ARADES trial, patients were randomly assigned to
receive ODM-201 at doses between 200 and 1800 mg daily (phase 1)
and stratiﬁed by previous chemotherapy and treatment with CYP17i, and
to receive expanded dose levels of 200, 400, and 1400 mg daily (phase 2)
[14]. We report here the safety and efﬁcacy results for ARADES patients
with extended follow-up who were CYP17i- and chemotherapy-naïve or
CYP17i-naïve and chemotherapy-pretreated. All patients received oral
ODM-201 at doses between 100 and 900 mg twice daily, with each
patient’s treatment dose being the same dose that the patient received
at week 12 [14]. Patients were permitted one dose increase to the highest
tolerated dose identiﬁed as safe, but not beyond the highest phase
2 dose, and visited the study centre monthly for 6 mo, followed by visits
at 3-monthly intervals.
2.4. Antitumour activity assessment
Patients considered to have a complete response, partial response, or
stable disease continued treatment in the ARADES trial until disease
progression (time to conﬁrmed radiographic and/or to PSA progression,
as deﬁned by the Prostate Cancer Working Group 2, PCWG2 [15]) or until
they experienced an intolerable AE.
Soft tissue response was assessed via computed tomography/mag-
netic resonance imaging of the chest, abdomen and pelvis during the last
visit (before discontinuation or data cutoff). Changes in target lesions
were evaluated according to Response Evaluation Criteria in Solid
Tumors 1.1. Responses were assessed as complete response, partial
response, stable disease, progressive disease or not evaluable, strati-
ﬁed by dose and treatment group. Patients with conﬁrmed responses
for 6 mo were classiﬁed as durable responders. Changes in bone
lesions were assessed during the last visit and reported as improve-
ment, stable/no change, or progression by the investigator according to
PCWG2 criteria.
Clinical disease progression was determined by the investigator and
included loss of appetite/weight, change in bone pain/worsening bone
pain, increased use of analgesics, cachexia/decrease in performance scale
and other symptoms of progressive CRPC.
Table 1 – Patient demographics and clinical characteristics for the




Age, yr (range) 69 (53–83)
Median prostate-speciﬁc antigen, mg/ml (range) 94 (3–1294)
Measurable disease, n (%) 32 (41.6)
Change in soft tissue disease a
Disease progression at screening, n (%)
Prostate-speciﬁc antigen rise only 18 (23.4)
Radiographic with a rise in prostate-speciﬁc antigen 55 (71.4)
Radiographic without a rise in prostate-speciﬁc antigen4 (5.2)
Disease localisation at screening, n (%)
Bone only 29 (37.7)
Soft tissue only 13 (16.9)
Bone and soft tissue 34 (44.2)
None 1 (1.3)
Soft tissue disease metastasis site at screening, n (%)
No metastases 30 (39.0)
Visceral b 7 (9.1)
Other 35 (45.5)
Visceral b and other 5 (6.5)
Bone metastases at screening, n (%) 63 (81.8)
Circulating tumour cells (5 cells/7.5 ml of blood), n (%) 32 (41.6)




a Assessed using Response Evaluation Criteria in Solid Tumors criteria.
b Visceral included metastases in one or more of the following organs: liver,
lung, kidney.
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AEs were classiﬁed by system organ classes and preferred terms (Medical
Dictionary for Regulatory Activities coding system) and graded by National
Cancer Institute CommonTerminology Criteria for Adverse Events (version
4.03). Electrocardiograms (ECGs) and laboratory assessments (haematol-
ogy, serum chemistry, hormones and urine tests) were performed.
The initial analysis of this trial used a data cutoff of October 2013 [14];
safety data for patients still receiving the study drug at this time were
collected through to October 2014 and contributed to the extended
safety analysis.
2.6. Statistical analysis
Analyses of antitumour activity and safety were performed for patients
who received at least one dose of ODM-201. The Kaplan-Meier method
was used for time-to-progression analyses, with results reported as the
median values with associated 95% conﬁdence intervals (CIs) and inter-
quartile ranges (IQRs). The Cox proportional hazards model was used to
estimate hazard ratios (HRs) and associated 95% CIs. The log-rank test
was used to compare the median treatment duration between patient
subgroups. All safety data were summarised using descriptive statistics.
3. Results
3.1. Patients
A total of 77 patients with CYP17i-naïve CRPC had extended
follow-up during the ARADES trial and contributed to this
safety analysis; all received at least one dose of ODM-201
(safety population). Of the study cohort, 42 patients (54.5%)
were chemotherapy-naïve and 35 (45.5%) received prior
chemotherapy. Baseline demographic and clinical charac-
teristics are shown in Table 1.
The most common reason for discontinuation was dis-
ease progression (84.4% of patients), with five patients
(6.5%) discontinuing due to AEs and one patient withdraw-
ing consent. The median duration of ODM-201 treatment
for all patients was 8.2 mo (95% CI 5.6–11.0; IQR 2.8–13.5);
this was longer for the chemotherapy-naïve subgroup
(9.3 mo, 95% CI 6.9–13.0, IQR 4.1–15.8) than for chemother-
apy-pretreated patients (6.0 mo, 95% CI 2.9–8.4, IQR 2.8–
11.7; log-rank p = 0.0135). The median follow-up time (from
the start of study treatment to the end-of-study visit) was
9.2 mo (95% CI 6.8–12.0, IQR 3.7–14.8). Four patients (5.2%)
continued treatment on a named patient (compassionate)
use basis after they discontinued the study; the shortest
duration of compassionate use (from the time of study
discontinuation) was 9 mo, and the longest was 22 mo.
Combining the compassionate use time with the on-study
treatment time for these four patients resulted in a total on-
treatment time of 31 mo (minimum) to 53 mo (maximum).
One patient continued to take ODM-201 on compassionate
basis until November 2016, rendering analysis incomplete
for these patients. Overall, the longest follow-up time,
excluding compassionate use, was 35.4 mo.
3.2. Safety
At least one AE was experienced by 75 patients (97.4%), but
the majority (61.1%) were grade 1; only 24 patients (31.2%)reported grade 3 AEs, including one patient with grade
4 lymphoedema and two patients who died with grade
5 AEs (one staphylococcal infection and one PCa). The most
common grade 3 AE was anaemia, which occurred in four
patients (5.2%), while the most common AE of any grade
was fatigue/asthenia, reported by 27 patients (35.1%). Grade
3 fatigue/asthenia occurred in only two patients (2.6%), and
no higher-grade fatigue/asthenia events were reported. A
similar pattern of AEs was seen in each patient subgroup
and no dose-related trends were observed. Only one
reported AE (grade 2 fatigue) led to discontinuation and
was thought to be related to ODM-201. No dose reductions
were required throughout the study. The incidence of AEs
reported by CYP17i-naïve patients during this extended
follow-up was similar to that reported by the same patient
group during the main ARADES trial at the time of the
original cutoff date (October 3, 2013): fatigue/asthenia
was the most common AE of any grade (23 patients,
29.9%) and grade 3 fatigue/asthenia was reported by two
patients (2.6%). Furthermore, during the phase 1/2 of ARA-
DES, the most common grade 3 AEs were anaemia and pain,
reported by three patients (3.9%), and only one patient
(1.3%) had a grade 4 AE (lymphoedema).
Treatment-related AEs (TRAEs) occurred in 27 patients
(35.1%) and are listed in Table 2. The majority of TRAEs (63/
64, 98.4%) were grade 1/2 in severity, with grade 1 occurring
in 25 patients (32.5%). Two patients had single grade
2 TRAEs (asthenia and hot flush) and one patient experi-
enced a grade 3 fatigue event. The most common TRAEs
Table 2 – Treatment-related adverse events (AEs) occurring in more than one patient for the safety population (all doses 100–900 mg twice
daily) in the extension study until the end-of-study visit or the data cutoff date.
Treatment-related AEs, n (%)
Grade 1 Grade 2 Grade 3 Grade 4/5 Total (n = 77)
Any treatment-related AE 25 (32.5) 8 (10.4) 1 (1.3) 0 (0.0) 27 (35.1)
Common treatment-related AE
Fatigue/asthenia 6 (7.8) 4 (5.2) 1 (1.3) 0 (0.0) 8 (10.4)
Decreased appetite 4 (5.2) 0 (0.0) 0 (0.0) 0 (0.0) 4 (5.2)
Diarrhoea 4 (5.2) 0 (0.0) 0 (0.0) 0 (0.0) 4 (5.2)
Hot ﬂush 2 (2.6) 1 (1.3) 0 (0.0) 0 (0.0) 3 (3.9)
Arthralgia 1 (1.3) 2 (2.6) 0 (0.0) 0 (0.0) 2 (2.6)
Back pain 1 (1.3) 2 (2.6) 0 (0.0) 0 (0.0) 2 (2.6)
Constipation 2 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.6)
Flatulence 2 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.6)
Gynaecomastia 2 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.6)
Headache 2 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.6)
Myalgia 2 (2.6) 1 (1.3) 0 (0.0) 0 (0.0) 2 (2.6)
Nausea 1 (1.3) 1 (1.3) 0 (0.0) 0 (0.0) 2 (2.6)
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diarrhoea and decreased appetite, reported by four patients
(5.2%) for each; and hot flush, reported by three patients
(3.9%).
There was no relevant change in the frequency of the
most common TRAEs over study duration, as demonstrated
by the evaluation of these AEs within 1 and 2 yr of the
patients’ first dose (Table 3). Only two TRAEs were captured
during the second year of treatment (one new event of
constipation and one recurring hot flush, both grade 1).
In addition, no clinically significant changes in laboratory
tests, vital signs, or ECG parameters were observed over the
extended study period.
3.3. Antitumour activity
PSA analyses included 76 CYP17i-naïve patients who had
evaluable data. The majority of patients responded to ODM-
201 treatment at all doses tested, as shown in terms of the
maximum reduction of PSA from baseline (Fig. 1A).
Responder rates (maximum PSA change of 50%) were
68.3% for chemotherapy-naïve (n = 28/41) and 42.9% for
chemotherapy-pretreated (n = 15/35) patients. This is fur-
ther illustrated by plots of PSA concentration changes from
baseline over time by patient in Fig. 1B.
Patients’ last responses (before discontinuation or cutoff)
in soft tissue and bone lesions and clinical progression wereTable 3 – Treatment-related adverse events (AEs) reported by the
safety population (n = 77) within 1 and 2 yr of the first dose. a
Patients reporting treatment-
related AEs, n (%)
Within 1 yr Within 2 yr
Any treatment-related AE b 26 (34) 27 (35)
Fatigue 8 (10.4) 8 (10.4)
Decreased appetite 4 (5.2) 4 (5.2)
Diarrhoea 4 (5.2) 4 (5.2)
a Patient numbers: n = 77 for 0–1 yr and n = 28 for 1–2 yr.
b Events listed are those reported by 5% of patients for at least one time
point.assessed in the safety population. Soft tissue responses for
evaluable patients (n = 48) included one patient with a
complete response (receiving 200 mg/d of ODM-201), seven
patients with a partial response, and 16 with stable disease,
whereas 24 patients experienced progressive disease. Most
of the patients with progressive disease had received the
lower ODM-201 doses (200 mg/d, n = 6; 400 mg/d, n = 13).
Fig. 2 shows all patients (n = 13) who had either a complete
or partial response throughout the study, with six patients
classified as durable responders.
No new bone lesions were detected in the majority of
patients (n = 45, 58.4%); bone lesions were classified as
stable/no change in 48 patients (62.3%), and 25 patients
(32.5%) had progressed. Overall, 22 patients (28.6%) experi-
enced clinical progression; the most common clinical symp-
toms demonstrating clinical progression were worsening of
pain/increased use of analgesics (17 patients, 41.5%).
Time-to-progression analyses included all CYP17i-naïve
patients who started the main study treatment (n = 77); one
patient was excluded for time to PSA progression (25% and
5 ng/ml increase from baseline) analyses (n = 76 evaluable
patients). At the end of the study, the antitumour activity of
ODM-201 (all doses) was demonstrated in both subgroups.
The median time to PSA progression was 25.2 mo (95% CI
11.2–25.2, IQR 6.5–25.2) for all patients, 25.2 mo (95% CI
11.3–25.2, IQR 11.0–25.2) for chemotherapy-naïve patients,
and was not reached (NR) for chemotherapy-pretreated
patients (95% CI 5.5–NR, IQR 4.7–NR; Fig. 3A). The HR for
PSA progression was 0.55 (95% CI 0.23–1.33; p = 0.1854) for
chemotherapy-naïve compared with chemotherapy-pre-
treated patients, suggesting that although there were no
statistically significant differences between treatment
groups, there was a trend for improved antitumour activity
among chemotherapy-naïve patients. The median time to
radiographic progression was longer in the chemotherapy-
naïve than in the chemotherapy-pretreated group (14.0 mo,
95% CI 8.1–33.3, IQR 5.6–33.3 vs 7.2 mo, 95% CI 2.7–11.0, IQR
2.6–11.6; HR 0.41, 95% CI 0.22–0.79; p = 0.0073; Fig. 3B).
For patients receiving expanded ODM-201 dose levels
(n = 68; 200, 400 and 1400 mg/d), the HR for PSA progres-
sion was 0.47 (95% CI 0.12–1.82; p = 0.2743) for the
Fig. 1 – (A) Maximum prostate-specific antigen (PSA) change by prior treatment group and dose level. Left: chemotherapy-naïve, CYP17 inhibitor–naïve
patients (2 patients had no post-baseline data and therefore were considered as nonresponders; not shown). Right: chemotherapy-pretreated, CYP17
inhibitor–naïve patients. (B) PSA changes over time by patient, grouped by dose level.
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the 400 mg/d group when compared with the 200 mg/d
group. The median time to PSA progression was NR for the
groups receiving 200 and 1400 mg/d of ODM-201, and was
25.2 mo (95% CI 4.7–25.2, IQR 4.7–25.2) for patients receiv-
ing 400 mg/d.
4. Discussion
Extended follow-up for the ARADES trial showed that con-
tinued ODM-201 treatment was effective and well tolerated
for up to 35.4 mo at all doses tested. This favourable safetyprofile reflects that seen in the analysis of 12-wk data [14],
with the majority of AEs being mild and not considered
related to treatment. The overall pattern of tolerability
observed during extended ODM-201 therapy was appropri-
ate for the treatment of CRPC, which typically occurs in an
older population [16] in which anticancer treatment–
related side effects can be poorly tolerated [17]. Many
patients receiving AR-directed therapy are likely to have
multiple comorbidities and be taking several concomitant
medications. In fact, concerns regarding tolerability are a
major factor contributing to the low use of chemotherapy
among older men with PCa [18], while first-generation
androgen deprivation therapy may be associated with an
Fig. 2 – Swimmer plot of patients’ responses (n = 13) according to Response Evaluation Criteria in Solid Tumors. Each bar represents one patient and
indicates the duration of study treatment (mo). A right arrow cap indicates continued response (patient’s response [partial response or complete
response] at the last visit, before discontinuation). A durable responder is a patient who has a confirmed response for at least 183 d (6 mo).
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ments [20].
The safety profile of extended ODM-201 dosing is typical
for patients with advanced PCa and is in line with that
reported for other second-generation AR antagonists, such
as apalutamide [21], enzalutamide [22–25], and abiraterone
acetate [26,27], with low incidence of fatigue/asthenia, the
most common AE associated with AR antagonist treatment.
Furthermore, the frequency of AEs during this extension
trial is comparable to the incidence reported in the main
ARADES trial for this patient population. Fatigue/asthenia of
any grade was the most common AE, occurring in 30–35% of
patients, and the overall number of discontinuations was
also similar (2–6.5%), highlighting that extended exposure
to ODM-201 does not cause any additional safety concerns.
As well as a favourable safety profile, prolonged treat-
ment with ODM-201 led to continued disease suppression
throughout the trial at all dose levels and in all subpopula-
tions (Fig. 1). Radiographic assessment further supported
the antitumour activity of extended ODM-201 dosing
(Fig. 2); for example, the majority of patients (62%) had
no bone metastases progression, similar to the bone scan
assessment data reported for CYP17i-naïve patients in the
main ARADES trial [14].
As expected, chemotherapy-naïve patients tended to
respond better to treatment, and the higher doses (eg,
1400 mg/d) appeared to provide the best PSA suppression
in these patients, in line with the analysis of the 12-wk
efficacy data (86% PSA response in chemotherapy-naïvepatients) [14]. The sustained PSA reductions and 14-mo
time to radiographic progression observed here for chemo-
therapy-naïve patients are also consistent with the ARAFOR
trial, in which the median time to radiographic progression
was 15 mo (daily dose of 1200 mg) [28].
Although a trend towards a dose-dependent efficacy
response was observed, there were no dose-related toxi-
cities, in line with results from the phase 1/2 of the ARADES
trial [14]. Previous pharmacokinetic analyses showed a
dose-dependent, linear increase in ODM-201 exposure in
patients receiving up to 1400 mg/d, but no further increase
with ODM-201 doses 1800 mg/d, suggesting that the tox-
icity profile of this compound is not related to its pharma-
cokinetic profile [14].
Emphasising the tolerability and efficacy of ODM-201,
one patient continued treatment on a named patient (com-
passionate) use programme until November 2016 and
benefited from the treatment. Furthermore, four patients
remained on treatment for a total of 31–53 mo, rendering
safety analysis incomplete for these patients.
The main limitations of this study were the open-label,
non-randomised study design [14], the relatively small
number of patients included in the extended follow-up
analyses, and the bias inherent in any follow-up trial. Any
patient remaining on treatment at the end of the study will
have already demonstrated tolerability for the agent over
time. These responders are typically patients who benefited
from androgen deprivation therapy over a long period
before developing CRPC [29]. The absence of quality-of-life
Fig. 3 – Kaplan-Meier plots showing time to (A) prostate-specific antigen progression and (B) radiographic progression. CYP17i = CYP17 inhibitor;
CI = confidence interval; NR = not reached.
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cognitive impairments have been associated with AR ther-
apy [19,20]. Future trials evaluating the impact of prolonged
ODM-201 treatment on QoL and cognitive functions are
needed and could potentially differentiate ODM-201 from
other treatment options for CRPC.
Overall, the favourable safety and efficacy observed dur-
ing this extended follow-up support further evaluation of
ODM-201 in placebo-controlled phase 3 trials. In the ARA-
MIS trial (NCT02200614), metastases-free survival is being
evaluated in patients with nonmetastatic CRPC receiving
ODM-201 [30]. In the ARASENS trial (NCT02799602), the
overall survival of ODM-201–treated patients with meta-
static castration-sensitive PCa will be assessed.
5. Conclusions
Extended exposure to ODM-201 is well tolerated, with no
additional safety concerns. This safety profile coupled with
clinical activity and sustained disease suppression indicates
that ODM-201 may represent a new treatment option for
patients with CRPC.
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